Study S000295

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (MARITIME 3-J)

ClinicalTrials.gov record

Registration

Registration: NCT06987695
Acronym: MARITIME-3-J
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 279
Start: 2025-06-13
Primary completion: 2027-04-27
Lead sponsor: Amgen
Conditions: Obesity Disease
Interventions: DRUG:Maridebart cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 72 [Baseline and Week 72]
Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 72 [Baseline and Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.